Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Рак молочной железы

9. Список литературы

  1. DeVita Jr., Rosenberg S.A., Lawrence T.S. Cancer: Principles & Practice of Oncology. Tenth Edition // LWW. P. 2280.
  2. Каприн А.Д., Старинский В.В,, Петрова Г.В. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 250 p.
  3. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2017 году. Москва: МНИОИ им. П.А. Герцена –филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 236 p.
  4. Members of the Breast Cancer Disease Site Group. Baseline staging tests in primarybreast cancer. Cancer Care Ontario, 2011.
  5. Tevaarwerk A.J., Wisinski K.B., O’Regan R.M. Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer // J. Oncol. Pract. 2016. Vol. 12, № 11. P. 1148– 1156.
  6. Obrzut M. et al. Does fine-needle aspiration biopsy still have a place in the diagnosis of breast lesions? // Przeglad Menopauzalny Menopause Rev. 2018. Vol. 17, № 1. P. 28–31.
  7. Асель Кудайбергенова. Перевод рекомендаций CAP. Протокол исследования инвазивного рака молочной железы. Общероссийская общественная организация«Российское общество онкомаммологов», 2016.
  8. Zhang Y., Ren H. Meta-analysis of diagnostic accuracy of magnetic resonance imaging and mammography for breast cancer // J. Cancer Res. Ther. 2017. Vol. 13, № 5. P. 862–868.
  9. Houssami N., Turner R.M., Morrow M. Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer // Breast Cancer Res. Treat. 2017. Vol. 165, № 2. P. 273–283.
  10. Rusch P. et al. Distant metastasis detected by routine staging in breast cancer patients participating in the national German screening programme: consequences for clinical practice // SpringerPlus. 2016. Vol. 5, № 1. P. 1010.
  11. Margolese R.G. et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial // Lancet Lond. Engl. 2016. Vol. 387, № 10021. P. 849– 856.
  12. Hong S., Li J., Wang S. 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis // Surg. Oncol. 2013. Vol. 22, № 2. P. 139–143.
  13. Cook G.J.R., Azad G.K., Goh V. Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment // J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2016. Vol. 57 Suppl 1. P. 27S-33S.
  14. Cagney D.N. et al. Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer // JAMA Oncol. 2018. Vol. 4, № 7. P. 1001– 1003.
  15. Cancer.Net Editorial Board. EKG and Echocardiogram // Navigating Cancer Care. American Society of Clinical Oncology.
  16. Любченко Л.Н. et al. Наследственный рак молочной железы: генетическая и клиническая гетерогенность, молекулярная диагностика, хирургическая профилактика в группах риска // Успехи молекулярной онкологии. № 2. P. 16–25.
  17. Cardoso F. et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2018. Vol. 29, № 8. P. 1634–1657.
  18. Hughes L.L. et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009. Vol. 27, № 32. P. 5319–5324.
  19. Marinovich M.L. et al. The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta- Analysis // Ann. Surg. Oncol. 2016. Vol. 23, № 12. P. 3811–3821.
  20. Siponen E. et al. Surgical treatment in Paget’s disease of the breast // Am. J. Surg. 2010. Vol. 200, № 2. P. 241–246.
  21. Семиглазов В.Ф., Палтуев Р.М. Клинические рекоменжации РООМ по диагностике и лечению рака молочной железы. 2018.
  22. Mok C.W. et al. Network meta- analysis of novel and conventional sentinel lymph node biopsy techniques in breast cancer // BJS Open. 2019.
  23. Хамитов А.Р. et al. Разработка алгоритма для сохранения проекционного лоскута кожи над опухолью при планировании подкожной мастэктомии из эстетически приемлемой зоны у пациенток с раком молочной железы узловой формы // Опухоли Женской Репродуктивной Системы. 2016. № 3. P. 23–29.
  24. Lyman G.H. et al. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017. Vol. 35, № 5. P. 561–564.
  25. Lyman G.H. et al. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017. Vol. 35, № 5. P. 561–564.
  26. Giuliano A.E. et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial // JAMA. 2017. Vol. 318, № 10. P. 918–926.
  27. Портной С.М., Кузнецов А.В., Шакирова Н.М. Биопсия сигнального лимфатического узла с использованием флуоресцентной лимфографии у больных раком молочной железы cT1-4N0M0: высокие диагностические возможности // Вопросы онкологии. 2019. № 2. P. 243–249.
  28. Криворотько П.В. Клинические рекоменжации РООМ по диагностике и лечению рака молочной железы. 2018.
  29. Giuliano A.E. et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial // JAMA. 2017. Vol. 318, № 10. P. 918–926.
  30. Lyman G.H. et al. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017. Vol. 35, № 5. P. 561–564.
  31. Caudle A.S. et al. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2016. Vol. 34, № 10. P. 1072–1078.
  32. Cabıoğlu N. et al. Improved False-Negative Rates with Intraoperative Identification of Clipped Nodes in Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy // Ann. Surg. Oncol. 2018. Vol. 25, № 10. P. 3030–3036.
  33. Donker M. et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure // Ann. Surg. 2015. Vol. 261, № 2. P. 378–382.
  34. Houssami N. et al. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis // Ann. Surg. Oncol. 2014. Vol. 21, № 3. P. 717–730.
  35. Choi J. et al. Margins in Breast-Conserving Surgery After Neoadjuvant Therapy // Ann. Surg. Oncol. 2018. Vol. 25, № 12. P. 3541–3547.
  36. Budach W. et al. DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases // Strahlenther. Onkol. Organ Dtsch. Rontgengesellschaft Al. 2015. Vol. 191, № 8. P. 623–633.
  37. Lightowlers S.V. et al. Preoperative breast radiation therapy: Indications and perspectives // Eur. J. Cancer Oxf. Engl. 1990. 2017. Vol. 82. P. 184–192.
  38. Fisher B. et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer // N. Engl. J. Med. 2002. Vol. 347, № 16. P. 1233–1241.
  39. Божок А.А. et al. Оценка результатов НИР РООМ «Возможности хирургического лечения больных раком молочной железы IV стадии» // Опухоли женской репродуктивной системы. 106AD. № 4. P. 17–24.
  40. Storto G. et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases // Bone. 2006. Vol. 39, № 1. P. 35–41.
  41. Radiation Therapy and Oncology Group 517. Randomized phase III trial to evaluate radiopharmaceuticals and Zoledronic Acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer.
  42. Chaichana K.L. et al. Survival and recurrence for patients undergoing surgery of skull base intracranial metastases // J. Neurol. Surg. Part B Skull Base. 2013. Vol. 74, № 4. P. 228– 235.
  43. Зикириходжаев А.Д., Ермощенкова А.Х., Исмагилов С.М. Клинические рекоменжации РООМ по диагностике и лечению рака молочной железы. 2018.
  44. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials // Lancet Lond. Engl. 2011. Vol. 378, № 9804. P. 1707–1716.
  45. Virnig B.A. et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes // J. Natl. Cancer Inst. 2010. Vol. 102, № 3. P. 170–178.
  46. Goodwin A. et al. Post-operative radiotherapy for ductal carcinoma in situ of the breast--a systematic review of the randomised trials // Breast Edinb. Scotl. 2009. Vol. 18, № 3. P. 143–149.
  47. Трофимова О.П. Стратегия лучевой терапии в органосберегающем лечении больных раком молочной железы. Диссертация на соискание учёной степени доктора медицинских наук. Москва, 2015.
  48. Curigliano G. et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2017. Vol. 28, № 8. P. 1700–1712.
  49. Haviland J.S. et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials // Lancet Oncol. 2013. Vol. 14, № 11. P. 1086– 1094.
  50. Bartelink H. et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial // Lancet Oncol. 2015. Vol. 16, № 1. P. 47–56.
  51. Jagsi R. et al. Locoregional recurrence rates and prognostic factors for failure in node- negative patients treated with mastectomy: implications for postmastectomy radiation // Int. J. Radiat. Oncol. Biol. Phys. 2005. Vol. 62, № 4. P. 1035–1039.
  52. Budach W. et al. Adjuvant radiotherapy of regional lymph nodes in breast cancer - a meta- analysis of randomized trials // Radiat. Oncol. Lond. Engl. 2013. Vol. 8. P. 267.
  53. Berry T. et al. Complication rates of radiation on tissue expander and autologous tissue breast reconstruction // Ann. Surg. Oncol. 2010. Vol. 17 Suppl 3. P. 202–210.
  54. Chow E. et al. Palliative radiotherapy trials for bone metastases: a systematic review // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007. Vol. 25, № 11. P. 1423–1436.
  55. Souchon R. et al. DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer: bone metastases and metastatic spinal cord compression (MSCC) // Strahlenther. Onkol. Organ Dtsch. Rontgengesellschaft Al. 2009. Vol. 185, № 7. P. 417– 424.
  56. Foro Arnalot P. et al. Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction // Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2008. Vol. 89, № 2. P. 150–155.
  57. Hayashi S., Hoshi H., Iida T. Reirradiation with local-field radiotherapy for painful bone metastases // Radiat. Med. 2002. Vol. 20, № 5. P. 231–236.
  58. Mithal N.P., Needham P.R., Hoskin P.J. Retreatment with radiotherapy for painful bone metastases // Int. J. Radiat. Oncol. Biol. Phys. 1994. Vol. 29, № 5. P. 1011–1014.
  59. Sahgal A., Larson D.A., Chang E.L. Stereotactic body radiosurgery for spinal metastases: a critical review // Int. J. Radiat. Oncol. Biol. Phys. 2008. Vol. 71, № 3. P. 652–665.
  60. Gibbs I.C. et al. Image-guided robotic radiosurgery for spinal metastases // Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2007. Vol. 82, № 2. P. 185–190.
  61. Gerszten P.C. et al. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution // Spine. 2007. Vol. 32, № 2. P. 193–199.
  62. Amdur R.J. et al. A prospective, phase II study demonstrating the potential value and limitation of radiosurgery for spine metastases // Am. J. Clin. Oncol. 2009. Vol. 32, № 5. P. 515–520.
  63. Chang E.L. et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure // J. Neurosurg. Spine. 2007. Vol. 7, № 2. P. 151–160.
  64. Nelson J.W. et al. Stereotactic body radiotherapy for lesions of the spine and paraspinal regions // Int. J. Radiat. Oncol. Biol. Phys. 2009. Vol. 73, № 5. P. 1369–1375.
  65. Tsai J.-T. et al. Assessment of image-guided CyberKnife radiosurgery for metastatic spine tumors // J. Neurooncol. 2009. Vol. 94, № 1. P. 119–127.
  66. A randomised phase III trial of two fractionation schemes in the treatment of malignant spinal cord compression. The All Ireland Cooperative Oncology Research Group.
  67. Patchell R.A. et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial // Lancet Lond. Engl. 2005. Vol. 366, № 9486. P. 643–648.
  68. Wu J.S.-Y. et al. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases // Int. J. Radiat. Oncol. Biol. Phys. 2003. Vol. 55, № 3. P. 594–605.
  69. Roos D.E. et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05) // Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2005. Vol. 75, № 1. P. 54–63.
  70. Cortazar P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis // Lancet Lond. Engl. 2014. Vol. 384, № 9938. P. 164–172.
  71. DeMichele A. et al. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer // Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2015. Vol. 21, № 13. P. 2911–2915.
  72. Семиглазов В.Ф., Манихас Г.М., Палтуев Р.М. Клинические рекомендации РООМ [Electronic resource] // Российское общество онкомаммологов. URL: http://breastcancersociety.ru/rek/view/227 (accessed: 11.08.2019).
  73. Gnant M., Harbeck N., Thomssen C. St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment // Breast Care Basel Switz. 2017. Vol. 12, № 2. P. 102–107.
  74. Sharma P. et al. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts // Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2017. Vol. 23, № 3. P. 649–657.
  75. Gianni L. et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort // Lancet Lond. Engl. 2010. Vol. 375, № 9712. P. 377–384.
  76. Gianni L. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial // Lancet Oncol. 2012. Vol. 13, № 1. P. 25–32.
  77. Schneeweiss A. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2013. Vol. 24, № 9. P. 2278– 2284.
  78. Semiglazov V.F. et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer // Cancer. 2007. Vol. 110, № 2. P. 244–254.
  79. Penault-Llorca F., Radosevic-Robin N. Ki67 assessment in breast cancer: an update // Pathology (Phila.). 2017. Vol. 49, № 2. P. 166–171.
  80. Rossi D. et al. Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer // Anticancer. Drugs. 2008. Vol. 19, № 7. P. 733–737.
  81. Mamounas E.P. et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27 // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2012. Vol. 30, № 32. P. 3960–3966.
  82. Heys S.D., Sarkar T., Hutcheon A.W. Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival // Breast Cancer Res. Treat. 2005. Vol. 90, № 2. P. 169–185.
  83. Gianni L. et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy // Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2005. Vol. 11, № 24 Pt 1. P. 8715–8721.
  84. Valero V. et al. Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience // Clin. Breast Cancer. 2002. Vol. 3 Suppl 2. P. S63-68.
  85. Gonzalez-Angulo A.M. et al. Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer // Clin. Breast Cancer. 2008. Vol. 8, № 6. P. 516–521.
  86. Ohnoa S. et al. Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer // Biomed. Pharmacother. Biomedecine Pharmacother. 2005. Vol. 59 Suppl 2. P. S323-324.
  87. Heller W. et al. Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer // Oncol. Rep. 2007. Vol. 17, № 1. P. 253–259.
  88. Green M.C. et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2005. Vol. 23, № 25. P. 5983–5992.
  89. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials // Lancet Lond. Engl. 2012. Vol. 379, № 9814. P. 432–444.
  90. Fujii T. et al. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis // JAMA Oncol. 2015. Vol. 1, № 9. P. 1311–1318.
  91. Watanabe T. et al. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study // Cancer. 2017. Vol. 123, № 5. P. 759–768.
  92. Henderson I.C. et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node- positive primary breast cancer // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2003. Vol. 21, № 6. P. 976–983.
  93. Sparano J.A. et al. Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer // N. Engl. J. Med. 2008. Vol. 358, № 16. P. 1663–1671.
  94. Levine M. Epirubicin in breast cancer: present and future // Clin. Breast Cancer. 2000. Vol. 1 Suppl 1. P. S62-67.
  95. Galligioni E. et al. High dose epirubicin and cyclophosphamide (EC) vs cyclophosphamide, methotrexate, fluorouracil (CMF) as adjuvant chemotherapy in high risk premenopausalbreast cancer patients (PTS). A prospective randomized trial // Eur. J. Cancer. 1998. Vol. 34, № 1001. P. S36.
  96. Bontenbal M. et al. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group // Br. J. Cancer. 1998. Vol. 77, № 12. P. 2257–2263.
  97. Bacrie J. et al. Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution // Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer. 2018. Vol. 26, № 12. P. 4097– 4103.
  98. Cameron D. et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial // Lancet Lond. Engl. 2017. Vol. 389, № 10075. P. 1195–1205.
  99. Hurvitz S.A. et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial // Lancet Oncol. 2018. Vol. 19, № 1. P. 115–126.
  100. Slamon D. et al. Adjuvant trastuzumab in HER2-positive breast cancer // N. Engl. J. Med. 2011. Vol. 365, № 14. P. 1273–1283.
  101. Perez E.A. et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011. Vol. 29, № 25. P. 3366–3373.
  102. Семиглазова Т.Ю., Ульрих Е.А., Семиглазов В.В. Место овариальной супрессии при раке молочной железы. 2018. 66 p.
  103. Saha P. et al. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017. Vol. 35, № 27. P. 3113–3122.
  104. Criscitiello C. et al. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node- positive breast cancer // Breast Edinb. Scotl. 2014. Vol. 23, № 1. P. 69–75.
  105. Francis P.A. et al. Adjuvant ovarian suppression in premenopausal breast cancer // N. Engl. J. Med. 2015. Vol. 372, № 5. P. 436–446.
  106. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient- level meta-analysis of randomised trials // Lancet Lond. Engl. 2011. Vol. 378, № 9793. P. 771–784.
  107. Davies C. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial // Lancet Lond. Engl. 2013. Vol. 381, № 9869. P. 805–816.
  108. Regan M.M. et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up // Lancet Oncol. 2011. Vol. 12, № 12. P. 1101–1108.
  109. Cuzick J. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial // Lancet Oncol. 2010. Vol. 11, № 12. P. 1135–1141.
  110. Derks M.G.M. et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial // Lancet Oncol. 2017. Vol. 18, № 9. P. 1211–1220.
  111. Gnant M. et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial // Lancet Lond. Engl. 2015. Vol. 386, № 9992. P. 433–443.
  112. Aurilio G. et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases // Eur. J. Cancer Oxf. Engl. 1990. 2014. Vol. 50, № 2. P. 277–289.
  113. Schrijver W.A.M.E. et al. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis // J. Natl. Cancer Inst. 2018. Vol. 110, № 6. P. 568– 580.
  114. Ieni A. et al. Letter to the Editor regarding the paper by Aurilio et al., A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases // Eur. J. Cancer Oxf. Engl. 1990. 2014. Vol. 50, № 5. P. 1035–1037.
  115. Cardoso F. et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) // Breast Edinb. Scotl. 2014. Vol. 23, № 5. P. 489–502.
  116. Nabholtz J.M. et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2000. Vol. 18, № 22. P. 3758–3767.
  117. Mouridsen H. et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2003. Vol. 21, № 11. P. 2101–2109.
  118. Patterson-Lomba O. et al. Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer // Breast J. 2019.
  119. Milla-Santos A. et al. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer // Breast Cancer Res. Treat. 2001. Vol. 65, № 2. P. 119–124.
  120. Ellis A.J. et al. Selective estrogen receptor modulators in clinical practice: a safety overview // Expert Opin. Drug Saf. 2015. Vol. 14, № 6. P. 921–934.
  121. Metindir J., Aslan S., Bilir G. Ovarian cyst formation in patients using tamoxifen for breast cancer // Jpn. J. Clin. Oncol. 2005. Vol. 35, № 10. P. 607–611.
  122. Henry N.L. et al. Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation // Clin. Breast Cancer. 2017. Vol. 17, № 5. P. 350- 355.e4.
  123. Anderson R.A. et al. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer // Eur. J. Cancer Oxf. Engl. 1990. 2017. Vol. 87. P. 58–64.
  124. Nabholtz J.M. et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2000. Vol. 18, № 22. P. 3758–3767.
  125. Mouridsen H. et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2001. Vol. 19, № 10. P. 2596–2606.
  126. Finn R.S. et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 // Breast Cancer Res. BCR. 2016. Vol. 18, № 1. P. 67.
  127. O’Shaughnessy J. et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial // Breast Cancer Res. Treat. 2018. Vol. 168, № 1. P. 127–134.
  128. Hortobagyi G.N. et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2- negative advanced breast cancer // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2018. Vol. 29, № 7. P. 1541–1547.
  129. Paridaens R.J. et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008. Vol. 26, № 30. P. 4883–4890.
  130. Baselga J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer // N. Engl. J. Med. 2012. Vol. 366, № 6. P. 520–529.
  131. Di Leo A. et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010. Vol. 28, № 30. P. 4594– 4600.
  132. Robertson J.F.R. et al. Activity of fulvestrant in HER2-overexpressing advanced breast cancer // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2010. Vol. 21, № 6. P. 1246–1253.
  133. Finn R.S. et al. Palbociclib and Letrozole in Advanced Breast Cancer // N. Engl. J. Med. 2016. Vol. 375, № 20. P. 1925–1936.
  134. Slamon D.J. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2018. Vol. 36, № 24. P. 2465–2472.
  135. Cardoso F. et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2017. Vol. 28, № 1. P. 16–33.
  136. Kramer J.A. et al. Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist // Eur. J. Cancer Oxf. Engl. 1990. 2000. Vol. 36, № 12. P. 1488–1497.
  137. O’Brien M.E.R. et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2004. Vol. 15, № 3. P. 440–449.
  138. Hainsworth J.D. et al. Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial // Cancer Invest. 2006. Vol. 24, № 5. P. 469–473.
  139. Nelli F. et al. Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: a retrospective cohort analysis // J. Chemother. Florence Italy. 2013. Vol. 25, № 2. P. 112–118.
  140. Nabholtz J.M. et al. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer // Oncol. Williston Park N. 1997. Vol. 11, № 8 Suppl 8. P. 25–30.
  141. Perez null. Paclitaxel in Breast Cancer // The Oncologist. 1998. Vol. 3, № 6. P. 373–389.
  142. Lück H.J. et al. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer // Oncol. Williston Park N. 1997. Vol. 11, № 4 Suppl 3. P. 34–37.
  143. Perez E.A. et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2001. Vol. 19, № 22. P. 4216– 4223.
  144. Liu Y. et al. Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials // Oncotarget. 2017. Vol. 8, № 42. P. 72950–72958.
  145. Aapro M., Finek J. Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results // Cancer Treat. Rev. 2012. Vol. 38, № 2. P. 120–126.
  146. Lüftner D. et al. Gemcitabine for palliative treatment in metastatic breast cancer // J. Cancer Res. Clin. Oncol. 1998. Vol. 124, № 10. P. 527–531.
  147. Perez E.A. et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007. Vol. 25, № 23. P. 3407– 3414.
  148. Blum J.L. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer // The Oncologist. 2001. Vol. 6, № 1. P. 56–64.
  149. Talbot D.C. et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines // Br. J. Cancer. 2002. Vol. 86, № 9. P. 1367–1372.
  150. Cortes J. et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study // Lancet Lond. Engl. 2011. Vol. 377, № 9769. P. 914–923.
  151. Kaufman P.A. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2015. Vol. 33, № 6. P. 594–601.
  152. Cinieri S. et al. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer // Clin. Breast Cancer. 2017. Vol. 17, № 2. P. 91-99.e1.
  153. Li J. et al. Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study // Medicine (Baltimore). 2015. Vol. 94, № 41. P. e1340.
  154. Thomas E.S. et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007. Vol. 25, № 33. P. 5210–5217.
  155. Wagner L, Wang M, Miller K, et al. Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: results from the Eastern Cooperative Oncology Group (ECOG) study E2100. Breast Cancer Res Treat 2006;100(Suppl. 1):S239.
  156. Marty M. et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2- positive metastatic breast cancer administered as first-line treatment: the M77001 study group // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2005. Vol. 23, № 19. P. 4265–4274.
  157. Slamon D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 // N. Engl. J. Med. 2001. Vol. 344, № 11. P. 783–792.
  158. Kaufman B. et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009. Vol. 27, № 33. P. 5529–5537.
  159. Swain S.M. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double- blind, placebo-controlled, phase 3 study // Lancet Oncol. 2013. Vol. 14, № 6. P. 461–471.
  160. Stravodimou A., Zaman K., Voutsadakis I.A. Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series // ISRN Oncol. 2014. Vol. 2014. P. 289836.
  161. Bergen E. et al. Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer // Breast Care. 2014. Vol. 9, № 5. P. 344–348.
  162. Farhat F., Kattan J.G., Ghosn M. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer // Cancer Chemother. Pharmacol. 2016. Vol. 77, № 5. P. 1069–1077.
  163. von Minckwitz G. et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer // Eur. J. Cancer Oxf. Engl. 1990. 2011. Vol. 47, № 15. P. 2273–2281.
  164. Blackwell K.L. et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010. Vol. 28, № 7. P. 1124–1130.
  165. Verma S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer // N. Engl. J. Med. 2012. Vol. 367, № 19. P. 1783–1791.
  166. Geyer C.E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer // N. Engl. J. Med. 2006. Vol. 355, № 26. P. 2733–2743.
  167. Johnston S. et al. Lapatinib combined with letrozole versus letrozole and placebo as first- line therapy for postmenopausal hormone receptor-positive metastatic breast cancer // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009. Vol. 27, № 33. P. 5538–5546.
  168. Stockler M.R. et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011. Vol. 29, № 34. P. 4498–4504.
  169. Fedele P. et al. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer // Eur. J. Cancer Oxf. Engl. 1990. 2012. Vol. 48, № 1. P. 24–29.
  170. Martín M. et al. Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis // The Oncologist. 2015. Vol. 20, № 2. P. 111–112.
  171. Briasoulis E. et al. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer // Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2009. Vol. 15, № 20. P. 6454–6461.
  172. Addeo R. et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer // Clin. Breast Cancer. 2010. Vol. 10, № 4. P. 301–306.
  173. Montagna E. et al. 1876 A phase II study of metronomic oral chemotherapy for metastatic breast cancer patients: Safety and efficacy results of vinorelbine, cyclophosphamide plus capecitabine (VEX) combination // Eur. J. Cancer. 2015. Vol. 51. P. S291–S292.
  174. Cazzaniga M.E. et al. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study // Breast Edinb. Scotl. 2019. Vol. 48. P. 7–16.
  175. Yoshimoto M. et al. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer // Cancer Chemother. Pharmacol. 2012. Vol. 70, № 2. P. 331–338.
  176. Wang H. et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer // PloS One. 2012. Vol. 7, № 4. P. e34210.
  177. Addeo R. et al. Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases // Cancer Chemother. Pharmacol. 2012. Vol. 70, № 4. P. 603–609.
  178. Colleoni M. et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2002. Vol. 13, № 1. P. 73–80.
  179. Colleoni M. et al. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00 // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2016. Vol. 34, № 28. P. 3400– 3408.
  180. Schmid P. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer // N. Engl. J. Med. 2018. Vol. 379, № 22. P. 2108–2121.
  181. Coates A.S. PG 0.1 Evolution of the St.Gallen Consensus process for the optimal treatment of women with breast cancer // The Breast. 2015. Vol. 24. P. S1.
  182. Byrski T. et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients // Breast Cancer Res. Treat. 2014. Vol. 147, № 2. P. 401–405.
  183. Tutt A. et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial // Nat. Med. 2018. Vol. 24, № 5. P. 628–637.
  184. Contrast Manual [Electronic resource]. URL: https://www.acr.org/Clinical- Resources/Contrast-Manual (accessed: 18.09.2019).
  185. Amant F. et al. Breast cancer in pregnancy // Lancet Lond. Engl. 2012. Vol. 379, № 9815. P. 570–579.
  186. Loibl S. et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting // Cancer. 2006. Vol. 106, № 2. P. 237–246.
  187. Gentilini O. et al. Sentinel lymph node biopsy in pregnant patients with breast cancer // Eur.J. Nucl. Med. Mol. Imaging. 2010. Vol. 37, № 1. P. 78–83.
  188. Ellner S.J. et al. Dose-dependent biodistribution of [(99m)Tc]DTPA-mannosyl-dextran for breast cancer sentinel lymph node mapping // Nucl. Med. Biol. 2003. Vol. 30, № 8. P. 805– 810.
  189. Khera S.Y. et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping // Breast J. 2008. Vol. 14, № 3. P. 250–254.
  190. Peccatori F.A. et al. Weekly epirubicin in the treatment of gestational breast cancer (GBC) // Breast Cancer Res. Treat. 2009. Vol. 115, № 3. P. 591–594.
  191. Azim H.A. et al. Anthracyclines for gestational breast cancer: course and outcome of pregnancy // Ann. Oncol. 2008. Vol. 19, № 8. P. 1511–1512.
  192. Zagouri F. et al. Taxanes for breast cancer during pregnancy: a systematic review // Clin. Breast Cancer. 2013. Vol. 13, № 1. P. 16–23.
  193. Cullins S.L., Pridjian G., Sutherland C.M. Goldenhar’s syndrome associated with tamoxifen given to the mother during gestation // JAMA. 1994. Vol. 271, № 24. P. 1905– 1906.
  194. Isaacs R.J., Hunter W., Clark K. Tamoxifen as systemic treatment of advanced breast cancer during pregnancy--case report and literature review // Gynecol. Oncol. 2001. Vol. 80, № 3. P. 405–408.
  195. Tewari K. et al. Ambiguous genitalia in infant exposed to tamoxifen in utero // The Lancet. 1997. Vol. 350, № 9072. P. 183.
  196. Gottschalk I. et al. Fetal Renal Insufficiency Following Trastuzumab Treatment for Breast Cancer in Pregnancy: Case Report und Review of the Current Literature // Breast Care Basel Switz. 2011. Vol. 6, № 6. P. 475–478.
  197. Sekar R., Stone P.R. Trastuzumab use for metastatic breast cancer in pregnancy // Obstet. Gynecol. 2007. Vol. 110, № 2 Pt 2. P. 507–510.
  198. Watson W.J. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios // Obstet. Gynecol. 2005. Vol. 105, № 3. P. 642–643.
  199. Keyser E.A. et al. Pregnancy-associated breast cancer // Rev. Obstet. Gynecol. 2012. Vol. 5, № 2. P. 94–99.
  200. Sanson B.J. et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review // Thromb. Haemost. 1999. Vol. 81, № 5. P. 668–672.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
9. Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*